Healthcare Services

Chronic Spontaneous Urticaria Market Revenue Growth Expected to Reach $3.2 Billion by 2030 with 7.4% CAGR

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Chronic Spontaneous Urticaria Market From 2026 To 2030?

The chronic spontaneous urticaria market has experienced robust expansion in recent years. Forecasts indicate its valuation will rise from $2.23 billion in 2025 to $2.41 billion in 2026, propelled by a compound annual growth rate (CAGR) of 8.4%. This past growth is primarily driven by factors such as the rising prevalence of chronic skin allergies, enhanced access to second-generation antihistamines, more effective diagnostic procedures, an uptick in dermatology clinic attendance, and heightened patient understanding of urticaria conditions.

The chronic spontaneous urticaria market is projected to experience robust expansion in the coming years. By 2030, its valuation is anticipated to reach $3.21 billion, demonstrating a compound annual growth rate (CAGR) of 7.4%. This projected growth during the forecast period is fueled by several factors, including the expanding development pipeline for biologic drugs, heightened investment in autoimmune dermatology research, broader application of targeted monoclonal antibodies, an intensified focus on achieving symptom-free disease management, and the increasing uptake of long-term maintenance therapies. Key trends anticipated within the same period encompass the surging adoption of biologic treatments for CSU, an uptick in the utilization of advanced antihistamine protocols, a deepening focus on the underlying mechanisms of autoimmune diseases, the wider implementation of personalized treatment algorithms, and improved monitoring strategies for long-term disease control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Major Drivers Are Influencing Demand In The Chronic Spontaneous Urticaria Market?

A projected rise in alcohol intake is anticipated to drive the expansion of the chronic spontaneous urticaria market in the future. This upward trend in alcohol use stems from several influences, including societal customs, pressure, promotional activities, cost-effectiveness, and ease of access. For certain individuals, alcohol intake has the potential to worsen chronic spontaneous urticaria symptoms, resulting in more pronounced hives and swelling. While, for instance, a 2023 survey cited by the Priory Group, a UK-based provider of mental health, addiction, and specialist education services, reported that by 2025, 25% of UK individuals aged 18–24 now fully abstain from alcohol, highlighting a significant shift towards sobriety in the younger generation, the broader increase in alcohol consumption is ultimately fueling the expansion of the chronic spontaneous urticaria market.

Which Segments Are Included In The Analysis Of The Chronic Spontaneous Urticaria Market?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administrations

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy

Which Upcoming Trends Are Expected To Influence The Chronic Spontaneous Urticaria Market?

Major companies within the chronic spontaneous urticaria market are actively developing advanced next-generation Briquilimab (JSP191) to enhance treatment efficacy and reduce dosing frequency. Next-generation Briquilimab (JSP191) is characterized as a monoclonal antibody engineered to target and deplete specific immune cells, particularly those targeting CD47, which is relevant in chronic spontaneous urticaria. For instance, in November 2023, Jasper Therapeutics Inc., a US-based clinical-stage biotechnology company, announced that its first patient had been dosed in a Phase 1b/2a clinical study of Briquilimab for chronic spontaneous urticaria (CSU). This achievement marks a critical juncture in evaluating the safety and effectiveness of Briquilimab, a next-generation monoclonal antibody that targets CD47, in managing this recurrent hive and itching problem. The study aims to assess how effectively Briquilimab can alleviate symptoms and improve the quality of life for patients suffering from CSU.

Which Key Industry Participants Are Active In The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Read the full chronic spontaneous urticaria market report here:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2025. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Spontaneous Urticaria Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2026, By The Business Research Company

Online Legal Services Global Market Report

https://www.thebusinessresearchcompany.com/report/online-legal-services-global-market-report

Legal Services Global Market Report

https://www.thebusinessresearchcompany.com/report/legal-services-global-market-report

International Call Services Global Market Report

https://www.thebusinessresearchcompany.com/report/international-call-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795